Three headlines from 2026 capture how fast Indian Pharma Industry is going global: Sun Pharmaceutical Industries agreed to acquire US-listed Organon & Co. for an enterprise value of US$11.75 billion, the largest overseas acquisition in Indian pharmaceutical history; Dr Reddy’s Laboratories rolled out a generic anti-obesity medicine across roughly 87 international markets; and Wockhardt’s Zaynich became the first New Chemical Entity fully invented, developed and commercialised by an Indian company to win US FDA approval, after twenty-five years and roughly US$800 million of research. These are not incremental export wins, they mark a structural transition from a generics and manufacturing powerhouse to a science-led, innovation-driven global industry.India’s pharmaceutical industry has already demonstrated that it can compete globally on scale, cost and manufacturing capability. It is now demonstrating something else: that it can build companies capable of originating, not just manufacturing, medicine. Indian life-sciences companies are no longer simply exporting medicines manufactured at home once patents on the original molecules expire. They are acquiring companies in the United States and Europe, building subsidiaries and R&D operations abroad, entering specialty and innovative medicines, developing biosimilars and biologics, running patient-facing programmes and engaging with healthcare systems governed by regulatory and ethical frameworks quite different from those they have traditionally operated under in India.The implications of this shift extend well beyond regulatory registrations. As the business globalises, its compliance perimeter globalises with it — and does so faster than most organisational structures are built to absorb.
Can a compliance programme designed at an Indian headquarters travel effectively with the company into the United States, the European Union, the United Kingdom, Australia, Japan and Latin America?
The honest answer, after conversations with leaders across a number of Indian life-sciences organisations, is: not yet fully. That is not a criticism. It is a description of where a fast-globalising industry currently sits, and an invitation to think about what the next stage of maturity looks like.
From Generic Exporters to Global Life-Sciences Companies
Indian pharmaceutical companies have historically built their international success on generic medicines, active pharmaceutical ingredients and contract manufacturing. The United States remains central to that story: Indian pharmaceutical exports to the US were estimated at approximately US$8.7 billion in FY2024.
But the strategic direction is changing. Companies are moving into specialty pharmaceuticals, oncology, rare diseases, biosimilars, biologics, vaccines, diagnostics, medical devices, digital health, patient support services and cross-border R&D partnerships — and the nature of their international expansion is changing with it.
The Organon deal illustrates the point at scale: 70-plus medicines across some 140 countries, expected to lift Sun Pharma into the world’s top 25 pharmaceutical companies by revenue. Wockhardt’s Zaynich illustrates it at the level of science — this shift now extends to origination itself, not only manufacturing and formulation. A molecule built and proven entirely in India, cleared by the world’s most stringent regulator, carries clinical-trial, pharmacovigilance and post-market obligations of its own in every market it enters.
Biocon has built a substantial global biosimilars franchise; Zydus and others continue expanding innovative-medicines pipelines internationally. These are global operating strategies, and they require a global compliance architecture, not local add-ons to a domestic programme.
The Compliance Perimeter Expands with the Business
When an Indian pharmaceutical company expands globally, its footprint changes shape entirely. It may now own subsidiaries in the US and the EU, have acquired a Western biotech business, run clinical-development programmes, market specialty medicines, operate patient support programmes, engage with patient advocacy organisations, work with healthcare professionals and organisations in most stringent regimes, process patient health data, and participate in government reimbursement systems.
Its compliance perimeter changes just as fundamentally: the FCPA, FDA and False Claims Act regimes, SEC obligations, EU pharmaceutical and clinical-trial regulation, the GDPR, EU and UK competition and bribery law, sanctions regimes, and local promotional and patient-engagement codes in every market it touches.
The change here is not simply more jurisdictions to track — it is a change in the type of risk, from largely manufacturing, distributor and HCP risk to clinical-data integrity, patient engagement, reimbursement and product-liability risk. Scale and complexity are different problems.
The challenge is not simply knowing each law. It is building a system capable of translating dozens of overlapping requirements into consistent operational behaviour across many countries at once — without either paralysing the business or leaving it exposed.
Enforcement History Already Provides the Warning
The risk is not theoretical. There have been instances ranging from concluded criminal settlements, through warning letters and inspection findings, to investigations closed without any enforcement action at all. Conflating these categories would be misleading, and each is described here for what it actually was.
Ranbaxy: When a Manufacturing Problem Becomes a Global Corporate Problem
In May 2013, Ranbaxy USA pleaded guilty to felony charges under the US Food, Drug and Cosmetic Act over adulterated drugs at two Indian facilities and false statements to the FDA, agreeing to pay US$500 million — the largest drug-safety settlement to date with a generic manufacturer.
The lesson is larger than manufacturing quality: a chain running from Indian manufacturing data, through regulatory submissions, into a US subsidiary and government healthcare programmes can convert a site-level failure into an enterprise-level, cross-border event.
Sun Pharmaceutical Industries received a similar warning letter in October 2023 over cGMP violations at its Halol facility — a routine-inspection finding, not the criminal conduct at issue in Ranbaxy.
Cipla: Continuing Scrutiny Even at Scale
A more instructive example is the FDA’s November 2023 warning letter to Cipla Limited concerning its Pithampur (Madhya Pradesh) facility. Alongside cGMP observations, the FDA found that Cipla had failed to submit a required Field Alert Report within three working days of a reportable event, as the Food, Drug and Cosmetic Act requires, an information-flow and escalation-governance failure, not merely a manufacturing one.
The underlying question is not “was the product manufactured correctly?” but whether the organisation could recognise a reportable event and act within a foreign regulator’s deadline. Regulatory intelligence, spotting a trigger early enough to act inside that deadline, is fast becoming a core corporate capability, not a by-product of quality assurance.
The Clinical Data Supply Chain: EMA and Synapse Labs
In 2024, following a Good Clinical Practice inspection that found irregularities in study data and weak computer systems, EMA recommended suspending marketing authorisations for the large majority of over 400 generic medicines whose bioequivalence relied on studies from Synapse Labs Pvt. Ltd, a Pune-based CRO.
The point is not that the CRO happened to be Indian-owned. Clinical data integrity questioned anywhere in the supply chain, own facilities, acquired facilities, or a third-party CRO, can suspend market access for many products at once. The regulatory perimeter, in other words, increasingly follows the product’s lifecycle rather than the company’s legal entity, wherever data, product responsibility or decision-making actually travels.
Dr Reddy’s: Investigation Exposure Without Enforcement
Following an anonymous complaint in November 2020 alleging improper payments to healthcare professionals in Ukraine, Dr Reddy’s disclosed the matter to the DOJ, SEC and SEBI, engaged US counsel, and cooperated for more than five years. On 23 February 2026 the SEC closed its investigation without recommending enforcement action; on 5 March 2026, DOJ’s Fraud Section closed its FCPA inquiry likewise.
This is not an enforcement action and should not be described as one, on its face, a vindication of the company’s cooperation and governance response. But the underlying five-year exposure is itself the lesson: global operations bring an Indian company within foreign regulators’ investigative jurisdiction regardless of outcome. And global compliance is not synonymous with anti-bribery compliance: in 2024 the European Commission issued a Statement of Objections, a preliminary allegation, not a finding, over an alleged cartel involving an active pharmaceutical ingredient, a reminder that competition law, sanctions and data protection belong in the same architecture as anti-bribery and quality compliance.
Innovation Brings a New Compliance Stakeholder Universe
Perhaps the most significant shift accompanies the move from traditional generics into innovative medicines, biologics and biosimilars. India is largely a patient payer market, and India’s pharmaceutical compliance conversation has historically centred on relationships with healthcare professionals, distributors, hospitals and regulators. The international specialty-pharma environment is considerably broader, and much of it, patient advocacy engagement, structured patient support programmes, has no close domestic Indian equivalent.
Patient Organisations
The UK’s ABPI Code, for example, contains specific provisions governing relationships with patient organisations, donations, grants, sponsorships and contracted services, each subject to defined safeguards and transparency requirements. Comparable expectations exist across most mature specialty-pharma markets.
For a company entering this space for the first time, new questions arise with no domestic precedent: who owns the relationship, was the organisation selected independently of any promotional objective, and is funding proportionate to a genuine need? These require a governance framework, not case-by-case calls.
The GLP-1 Moment: A Preview of What Is Coming
This is not distant. After Semaglutide’s March 2026 patent expiry in India, Dr Reddy’s and most other generics majors launched competing versions in rapid succession, and Dr Reddy’s separately rolled out a generic anti-obesity medicine across some 87 markets, India’s clearest entry yet into chronic weight management rather than acute disease treatment.
The GLP-1 category compresses a compliance profile traditional Indian generics have not had to manage, and at speed: obesity and metabolic-disease advocacy groups are actively courted by competing manufacturers; the medicines are widely prescribed off-label through a fast-growing D2C telehealth ecosystem; and much of the commercial activity runs through digital and social channels, including patient influencers. Expect these risks to arrive together, not sequentially.
Patient Support Programmes
As Indian companies move deeper into innovative and specialty medicine, the interface with patient support programmes becomes close to inevitable: these are now a standard feature of how innovative therapies are launched and adopted in mature markets, and a company entering that space will be expected to run one.
These programmes — adherence support, nurse counselling, reimbursement and financial assistance, enrolment and monitoring, typically involve the company, healthcare professionals, specialty pharmacies, technology vendors and, often, patient organisations. Critically, they usually involve health data.
Loosely designed, these programmes carry real legal exposure, not just reputational risk, particularly in the US, where a structured reimbursement pathway exists. US enforcement has repeatedly targeted arrangements where a co-pay-assistance structure ended up inducing use of a specific drug: in its FY2025 round-up, DOJ recorded Teva Pharmaceuticals’ agreement to pay US$425 million over allegations it used a foundation to cover Medicare patients’ Copaxone co-pays while steadily raising the price, violating the Anti-Kickback Statute and False Claims Act , one of many such settlements; the US Attorney’s Office in Massachusetts alone has collected over US$850 million from similar co-pay-conduit schemes. A programme without a clear boundary between genuine assistance and inducement to prescribe is an Anti-Kickback and False Claims Act exposure waiting to surface.
That data needs governing as carefully as it is collected. Patient support data should be ring-fenced from commercial and sales teams by design, access controls, purpose limitation, a clear governance line, so the company can show patient information was never used for sales targeting or promotional activity.
Under Article 9 of the EU GDPR, health data is a special category, processing of which is prohibited by default absent a specific statutory condition, so a patient support programme can implicate privacy, pharmacovigilance, medical-affairs and healthcare-fraud risk simultaneously, exactly the cross-functional risk a siloed compliance model is poorly designed to catch.
Cross-Border Acquisitions Change the Compliance Equation
An acquisition brings people, contracts and third-party relationships, and sometimes inherited misconduct that resurfaces as post-closing investigations. Zimmer Holdings’ 2015 acquisition of Biomet is a cautionary precedent: pre-acquisition FCPA misconduct at Biomet, first settled with the DOJ and SEC in 2012, resurfaced after the merger and cost the combined Zimmer Biomet a further US$30.5 million in 2017, successor liability the acquirer had to own regardless of when the conduct occurred.
This is best understood as a compliance transformation event that starts at strategic planning and continues for long after the deal closes. It also raises a cultural question: an Indian parent cannot assume a US or European target will adopt headquarters’ processes as-it-is, and imposing them wholesale often breeds resistance. The more durable objective is common principles, a common risk language and common escalation standards, with local implementation left to local teams.
US enforcement guidance treats this as a compliance-programme question, not only a transactional-risk one. DOJ’s Evaluation of Corporate Compliance Programs asks whether pre-acquisition due diligence is adequate, compliance is embedded in the M&A process, and the acquired entity is integrated effectively afterward.
For an Indian company acquiring a US or European business, due diligence cannot be a closing-condition checklist, it must run the full deal lifecycle: pre-signing risk mapping, remediation planning, and structured post-closing integration of people, policies, systems and third parties.
India Already Has the Governance Foundations
Global compliance maturity is not something Indian companies must import wholesale from the West. Indian corporate and securities law already contains the conceptual architecture; the task is to scale it for a multinational footprint.
Section 134 of the Companies Act, 2013 requires the Board’s Directors’ Responsibility Statement to confirm that the company has devised proper systems to ensure compliance with all applicable laws and that such systems are adequate and operating effectively, while section 177 places internal financial controls and risk management within the Audit Committee’s remit and section 166 requires directors to act with care, skill and independent judgment — together, a statutory basis for treating global regulatory exposure as a Board-level, not purely departmental, risk.
For listed companies, SEBI’s LODR Regulations require a Compliance Officer positioned no more than one level below the Board, and its BRSR Core framework extends value-chain ESG disclosure to major upstream and downstream partners, relevant given that a life-sciences company’s highest compliance risk often sits with a distributor, CRO or CMO rather than the parent entity.
India’s own Uniform Code for Pharmaceutical Marketing Practices, 2024 moves the same way, requiring disclosure of marketing expenditure incurred through third parties, the same documentation and transparency building blocks a global programme requires, applied domestically.
A Working Model: Global Minimum, Local Maximum
The answer is not a heavier policy library but an operating model: headquarters sets a global minimum standard no business unit may fall below, and each jurisdiction layers its own mandatory requirements on top — avoiding both an HQ policy exported wholesale, which misses local requirements, and every country building its own programme, which fragments the group’s view of its own risk.
| Traditional model | Global compliance model |
|---|---|
| Policy-centric | Risk-centric |
| HQ-driven | Globally governed, locally implemented |
| Annual training | Continuous, risk-based engagement |
| Third-party due diligence at onboarding | Third-party lifecycle management |
| Legal owns compliance | Business, Legal, Compliance, Medical Affairs, Market Access, and Quality share ownership |
| Reactive investigations | Speak-up channels plus proactive monitoring |
| Country-by-country programmes | Global minimum standards with local overlays |
| Policy certification | Evidence-based assurance |
| Annual Board compliance report | Risk dashboard briefed to the Board periodically |
A global minimum standard should address: anti-bribery; HCP and patient-organisation engagement; patient support programmes, jointly governed by legal, compliance, medical affairs and privacy; third-party risk across the full relationship lifecycle; data integrity; competition, sanctions and trade controls; privacy; and a single global investigations framework.
From Policy to Control
The most important discipline shift is from policy-centric to control-centric. For each material risk, the organisation should trace a line from risk, to requirement, to policy, to control, to owner, to evidence, to testing, to escalation. A policy stating HCP interactions must be “legitimate, reasonable and documented” is necessary but not sufficient; a mature system can also show who approved an interaction, why, and whether it was monitored. That is the difference between having a compliance programme and demonstrating that it works.
The DOJ’s own guidance frames the test in exactly these terms: is the programme well designed, is it adequately resourced and empowered to function effectively, and does it actually work in practice. “Can we prove the programme works?” is a more demanding question than “do we have a policy, a training programme and a hotline?”, and it is the one the Board should be asking.
A Five-Stage Maturity Model
Indian life-sciences companies can locate themselves against a simple maturity curve. The opportunity for many is to move deliberately from Stage 3 to Stage 4, and over time toward Stage 5.
| Stage | Model | Characteristics |
|---|---|---|
| 1 | Domestic compliance | Indian statutory and regulatory compliance only |
| 2 | Export compliance | Country-specific regulatory requirements layered on as needed |
| 3 | Multinational compliance | Foreign subsidiaries operating under group policies, applied unevenly |
| 4 | Integrated global compliance | Global minimum standards plus documented local regulatory overlays |
| 5 | Intelligent compliance | Continuous monitoring, analytics and technology-enabled control testing |
A Ten-Point Blueprint
Board ownership. Global regulatory exposure is a Board and Audit/Risk Committee matter, not purely departmental.
Global minimum standards. Headquarters defines non-negotiable principles that apply everywhere the company operates.
Local regulatory overlays. Every market translates those principles into its own mandatory requirements.
Risk-based prioritisation. Resources follow the highest regulatory and commercial risk, not the loudest local request.
Third-party lifecycle management. Distributors, CROs, CMOs and agents get due diligence and monitoring proportionate to risk, for the life of the relationship — collectively, this ecosystem often represents a larger compliance surface than the company’s own employees.
Patient-centric compliance. Patient organisations and support programmes get HCP-level governance, with patient data ring-fenced from commercial teams.
Data and evidence. Compliance must be demonstrable through evidence, not merely documented through policy.
Cross-border investigations. One global framework for reporting, triage, investigation and remediation across privilege and data-transfer boundaries.
M&A integration. Due diligence and integration run through the full deal lifecycle, including exposure to pre-acquisition misconduct.
Continuous improvement. Every audit finding, investigation, regulatory change and acquisition feeds back into the programme.
None of this works without culture. A blueprint can specify every control and escalation path, and still fail if employees believe raising a concern is career-limiting. The responsibility to cultivate the culture of “doing the right thing” cannot sit only within the compliance function, it has to run consistently across the organization, from the shop floor to the boardroom, and across every market the company operates in. That requires sustained, visible attention and action from leadership and the Board: what they ask about, measure, reward and tolerate under pressure. Culture determines whether the ten points above are lived practice or laminated posters, and it is built, or eroded, in exactly those moments.
A Practitioner’s Perspective
Having worked across India, Japan, Singapore and Australia, and across multiple markets within multinational life-sciences organisations, I have found that the most effective compliance programmes are rarely the ones with the largest policy libraries. They are the ones where global principles become clear local operating controls, ownership is unambiguous, escalation genuinely functions across borders, and the organisation can produce evidence, not just assurances, that controls operate as designed. That belongs at the same table as the business from the outset, not bolted on afterward.
Conclusion: When the Business Crosses Borders, Compliance Programs Must Meet Global Best Practices
India’s pharmaceutical industry has crossed a significant threshold: it has proven it can manufacture medicines, and increasingly develop them, for the world. The next threshold is less visible but no less important, whether Indian life-sciences companies can govern a global enterprise to the standard by which the world’s most credible pharmaceutical organisations are judged.
As Indian companies increasingly own businesses, run clinical programmes, engage patients and process health data abroad, under regulatory regimes reaching well beyond their headquarters, the imperative is straightforward: globalisation of the business must be accompanied by a compliance programme that meets, not merely references, global best practice.
India’s next competitive advantage may not simply be manufacturing medicines at globally competitive cost. It may be the ability to govern a globally integrated life-sciences business to the standards its most demanding regulators expect, without losing the speed, entrepreneurial culture and cost discipline that built India’s global pharmaceutical advantage.
This is not a suggestion that Indian companies import Western compliance wholesale. It is a call to build a globally credible architecture designed for an Indian multinational, globally governed, locally adaptable, risk-based and evidence-driven, capable of answering, with confidence, the one question every Board should be able to answer at any time:
If a regulator from another jurisdiction asked us tomorrow to demonstrate that our compliance programme works, could we?
(Views are personal)
